Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells

Cancer Immunology, Immunotherapy

Volumn 64, Issue 2, 2015, Pages 213-224

  André, Thibaud ^a   Najar, Mehdi ^a   Stamatopoulos, Basile ^a   Pieters, Karlien ^a   Pradier, Olivier ^c   Bron, Dominique ^b   Meuleman, Nathalie ^b   Lagneaux, Laurence ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c ERASME HOSPITAL   (Belgium)

Author keywords

Immunomodulation; MSCs; Myeloma; Th17 Treg

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; CYTOKINE;

ARTICLE; BONE MARROW; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; INFLAMMATION; MESENCHYMAL STROMA CELL; MIXED LYMPHOCYTE REACTION; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH17 CELL; COCULTURE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD40; COCULTURE TECHNIQUES; CYTOKINES; HUMANS; IMMUNOMODULATION; INFLAMMATION; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MESENCHYMAL STROMAL CELLS; MULTIPLE MYELOMA; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84925482125     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1623-y     Document Type: Article

References (49)

1. Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860–1873. doi:10.1056/NEJMra041875
2. Tucci M, Stucci S, Strippoli S, Dammacco F, Silvestris F (2011) Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression? Oncologist 16:1040–1048. doi:10.1634/theoncologist.2010-0327
3. Pratt G, Goodyear O, Moss P (2007) Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 138:563–579. doi:10.1111/j.1365-2141.2007.06705.x
4. Cook G, Campbell JD (1999) Immune regulation in multiple myeloma: the host–tumour conflict. Blood Rev 13:151–162. doi:10.1054/blre.1999.0111
5. Feyler S, von Lilienfeld-Toal M, Jarmin S, Marles L, Rawstron A, Ashcroft AJ, Owen RG, Selby PJ, Cook G (2009) CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 144:686–695. doi:10.1111/j.1365-2141.2008.07530.x
6. Favaloro J, Brown R, Aklilu E, Yang S, Suen H, Hart D, Fromm P, Gibson J, Khoo L, Ho PJ, Joshua D (2013) Myeloma skews Treg and Th17 cell balance in favor of a suppressive state. Leuk Lymphoma 55(5):1090–1098. doi:10.3109/10428194.2013.825905
7. Shen CJ, Yuan ZH, Liu YX, Hu GY (2012) Increased numbers of T helper 17 cells and the correlation with clinicopathological characteristics in multiple myeloma. J Int Med Res 40:556–564
8. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A, Dessoly J, Sciaini AK, Benbunan M, Chomienne C, Fermand JP, Marolleau JP, Larghero J (2007) Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 21:158–163. doi:10.1038/sj.leu.2404466
9. Li B, Fu J, Chen P, Zhuang W (2010) Impairment in immunomodulatory function of mesenchymal stem cells from multiple myeloma patients. Arch Med Res 41:623–633. doi:10.1016/j.arcmed.2010.11.008
10. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838–3843
11. Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H (2010) Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 185:302–312. doi:10.4049/jimmunol.0902007
12. + T cell activation. Immunol Lett 135:10–16. doi:10.1016/j.imlet.2010.09.006
13. English K, French A, Wood KJ (2010) Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell 7:431–442. doi:10.1016/j.stem.2010.09.009
14. Andre T, Meuleman N, Stamatopoulos B, De BC, Pieters K, Bron D, Lagneaux L (2013) Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. PLoS One 8:e59756. doi:10.1371/journal.pone.0059756
15. Najar M, Rouas R, Raicevic G, Boufker HI, Lewalle P, Meuleman N, Bron D, Toungouz M, Martiat P, Lagneaux L (2009) Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 11:570–583. doi:10.1080/14653240903079377
16. Horwitz EM, Le BK, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, Krause DS, Keating A (2005) Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 7:393–395. doi:10.1080/14653240500319234
17. Yellin MJ, Winikoff S, Fortune SM, Baum D, Crow MK, Lederman S, Chess L (1995) Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation. J Leukoc Biol 58:209–216
18. Dechanet J, Grosset C, Taupin JL, Merville P, Banchereau J, Ripoche J, Moreau JF (1997) CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol 159:5640–5647
19. O’Sullivan B, Thomas R (2003) CD40 and dendritic cell function. Crit Rev Immunol 23:83–107
20. Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM (2001) Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer 91:1219–1230
21. Yang ZX, Han ZB, Ji YR, Wang YW, Liang L, Chi Y, Yang SG, Li LN, Luo WF, Li JP, Chen DD, Du WJ, Cao XC, Zhuo GS, Wang T, Han ZC (2013) CD106 identifies a subpopulation of mesenchymal stem cells with unique immunomodulatory properties. PLoS One 8:e59354. doi:10.1371/journal.pone.0059354
22. Burkly LC, Jakubowski A, Newman BM, Rosa MD, Chi-Rosso G, Lobb RR (1991) Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferation. Eur J Immunol 21:2871–2875. doi:10.1002/eji.1830211132
23. Ren G, Zhao X, Zhang L, Zhang J, L’Huillier A, Ling W, Roberts AI, Le AD, Shi S, Shao C, Shi Y (2010) Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 184:2321–2328. doi:10.4049/jimmunol.0902023
24. Wakkach A, Cottrez F, Groux H (2001) Differentiation of regulatory T cells 1 is induced by CD2 costimulation. J Immunol 167:3107–3113
25. Chabannes D, Hill M, Merieau E, Rossignol J, Brion R, Soulillou JP, Anegon I, Cuturi MC (2007) A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 110:3691–3694. doi:10.1182/blood-2007-02-075481
26. Mougiakakos D, Jitschin R, Johansson CC, Okita R, Kiessling R, Le BK (2011) The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 117:4826–4835. doi:10.1182/blood-2010-12-324038
27. Zhang Y, Zhang L, Wu J, Di C, Xia Z (2013) Heme oxygenase-1 exerts a protective role in ovalbumin-induced neutrophilic airway inflammation by inhibiting Th17 cell-mediated immune response. J Biol Chem 288:34612–34626. doi:10.1074/jbc.M113.494369
28. Chan JL, Tang KC, Patel AP, Bonilla LM, Pierobon N, Ponzio NM, Rameshwar P (2006) Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 107:4817–4824. doi:10.1182/blood-2006-01-0057
29. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238. doi:10.1038/nature04753
30. Nasef A, Chapel A, Mazurier C, Bouchet S, Lopez M, Mathieu N, Sensebe L, Zhang Y, Gorin NC, Thierry D, Fouillard L (2007) Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr 13:217–226
31. Taga K, Mostowski H, Tosato G (1993) Human interleukin-10 can directly inhibit T-cell growth. Blood 81:2964–2971
32. + T cells. Arthritis Res Ther 11:257. doi:10.1186/ar2843
33. Nakae S, Iwakura Y, Suto H, Galli SJ (2007) Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol 81:1258–1268. doi:10.1189/jlb.1006610
34. Cipriani P, Di BP, Liakouli V, Del PB, Di PM, Di IM, Marrelli A, Alesse E, Giacomelli R (2013) Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. Clin Exp Immunol 173:195–206. doi:10.1111/cei.12111
35. Landgraf K, Brunauer R, Lepperdinger G, Grubeck-Loebenstein B (2011) The suppressive effect of mesenchymal stromal cells on T cell proliferation is conserved in old age. Transpl Immunol 25:167–172. doi:10.1016/j.trim.2011.06.007
36. Danese S, Sans M, Fiocchi C (2004) The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut 53:1035–1043
37. Massaia M, Bianchi A, Attisano C, Peola S, Redoglia V, Dianzani U, Pileri A (1991) Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex. Blood 78:1770–1780
38. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC (1995) CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 85:1903–1912
39. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, Anderson KC (2003) Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 63:6174–6177
40. Reinders ME, Sho M, Robertson SW, Geehan CS, Briscoe DM (2003) Proangiogenic function of CD40 ligand-CD40 interactions. J Immunol 171:1534–1541
41. Feuerbach D, Feyen JH (1997) Expression of the cell-adhesion molecule VCAM-1 by stromal cells is necessary for osteoclastogenesis. FEBS Lett 402:21–24. doi:10.1016/S0014-5793(96)01495-0
42. Wu TC (2007) The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Res 67:6003–6006. doi:10.1158/0008-5472.CAN-07-1543
43. Landowski TH, Olashaw NE, Agrawal D, Dalton WS (2003) Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene 22:2417–2421. doi:10.1038/sj.onc.1206315
44. Dhodapkar KM, Barbuto S, Matthews P, Kukreja A, Mazumder A, Vesole D, Jagannath S, Dhodapkar MV (2008) Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 112:2878–2885. doi:10.1182/blood-2008-03-143222
45. Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I (2010) A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 116:3554–3563. doi:10.1182/blood-2010-05-283895
46. Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, Gibson J, Ho PJ, Iland H, Fromm P, Woodland N, Nassif N, Hart D, Joshua DE (2013) Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J 3:e148. doi:10.1038/bcj.2013.34
47. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC (2001) The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20:4519–4527. doi:10.1038/sj.onc.1204623
48. Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, Muller GW, Stirling DI (2004) Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol 230:81–88. doi:10.1016/j.cellimm.2004.09.003
49. Noonan K, Rudraraju L, Ferguson A, Emerling A, Pasetti MF, Huff CA, Borrello I (2012) Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res 18:1426–1434. doi:10.1158/1078-0432.CCR-11-1221